OmniAb Q1 revenue $14.4M vs $4.2M YoY; raises 2026 guidance

OmniAb, Inc.

2026-Q1 EPS reported -$0.06 revenue$14,427,000

Revenue Q1 2026 $14.4M (up 243% YoY) driven by milestone revenue.
R&D expense $9.6M (down 24% YoY); G&A expense $6.6M (down 16% YoY).
Amortization included $2.9M non-cash impairment from discontinued small-molecule programs.
Cash operating expenses (non-GAAP) $12.3M, down from $14.7M YoY.
2026 revenue guidance raised; management highlights OmniUltra launch and partner progress.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

OmniAb, Inc. reported the three months ended March 31, 2026 results: revenue $14.4 million. Guidance raised.

Period: the three months ended March 31, 2026
Revenue: $14.4 million
Guidance: raised
Result: reported results

Exact text from the filing

as demonstrated by the launch of OmniUltra TM and our xPloration ® partner access program. ” First Quarter 2026 Financial Results Revenue for the first quarter of 2026 was $14.4 million , compared with $4.2 million for the same period in 2025 , with the increase primarily related to milestone revenue . Research and development expense was $9.6 million for the

View on SEC.gov

Browse all earnings releases →

OmniAb, Inc. filing history →

Source: SEC EDGAR

accession 0001846253-26-000035

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.